主要文件

查看所有文档

Y0000458

瑞格列奈

Name: 瑞格列奈
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

瑞格列奈, (S)-(+)-2-乙氧基-4- [N- [1-（2-哌啶苯基）-3-甲基-1-丁基] 氨基羰基甲基] 苯甲酸, Novonorm, Prandin

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₇H₃₆N₂O₄

化学文摘社编号:

135062-02-1

分子量:

452.59

NACRES:

NA.24

PubChem Substance ID:

329830968

UNSPSC Code:

41116107

MDL number:

MFCD00906179

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

repaglinide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N3CCCCC3)ccc1C(O)=O

InChI

1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1

InChI key

FAEKWTJYAYMJKF-QHCPKHFHSA-N

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Repaglinide for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

瑞格列奈是一种有效的短效胰岛素促分泌剂，可通过关闭胰岛β细胞质膜中的ATP敏感性钾（K_ATP）通道发挥作用。

瑞格列奈是一种有效的短效胰岛素促分泌剂，可通过关闭胰岛β细胞质膜中的ATP敏感性钾（K_ATP）通道发挥作用。它是一类新的胰岛素促分泌素，其结构上与磺酰脲无关，专为治疗2型糖尿病而开发。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study.

Christina Jarnert et al.

Diabetes & vascular disease research, 9(4), 287-295 (2012-03-02)

Microcirculatory and endothelial dysfunction are signs of cardiovascular engagement in patients with type 2 diabetes. This study tested whether glucose normalisation may reverse this. Thirty-nine T2DM patients (age 61±7 years, 58% females) with signs of mild diastolic dysfunction were randomised

Deaths in trials should always be reported.

Jeppe Schroll

BMJ (Clinical research ed.), 347, f4219-f4219 (2013-07-06)

Severe thrombocytopenia due to repaglinide in a patient with type 2 diabetes.

Hisayuki Katsuyama et al.

Diabetes care, 36(3), e36-e36 (2013-02-23)

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0000458	04061833803684